368 Shares in argenx SE (NASDAQ:ARGX) Bought by Fulton Bank N.A.

Fulton Bank N.A. purchased a new position in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 368 shares of the company’s stock, valued at approximately $226,000.

A number of other large investors have also recently bought and sold shares of ARGX. Bank of New York Mellon Corp boosted its stake in argenx by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,671 shares of the company’s stock worth $2,439,000 after purchasing an additional 164 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in argenx by 11.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,255 shares of the company’s stock worth $1,400,000 after purchasing an additional 339 shares during the period. Envestnet Asset Management Inc. boosted its stake in argenx by 13.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 62,999 shares of the company’s stock worth $27,092,000 after purchasing an additional 7,645 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of argenx by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 19,388 shares of the company’s stock worth $8,339,000 after acquiring an additional 1,438 shares during the period. Finally, Wealth Alliance lifted its stake in shares of argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after acquiring an additional 29 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Raymond James restated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Citigroup raised their target price on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Truist Financial raised their target price on shares of argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, JMP Securities increased their price target on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $645.61.

argenx Price Performance

Shares of NASDAQ ARGX opened at $656.26 on Friday. The company has a market cap of $39.62 billion, a PE ratio of -745.75 and a beta of 0.59. argenx SE has a 12 month low of $349.86 and a 12 month high of $663.78. The company has a 50-day simple moving average of $612.30 and a 200-day simple moving average of $546.56.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the previous year, the firm posted ($1.25) earnings per share. On average, analysts anticipate that argenx SE will post 2.2 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.